Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7638470 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL5365862 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL4924486 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL1019945 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL8380164 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL28212362 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL6892577 | 0.97 | THRB (0.50) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL7630035 | 0.97 | THRB (0.48) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL9218463 | 0.94 | THRB (0.48) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL15012282 | 0.94 | THRB (0.48) | THRBLMNACA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | THRB 2180/4885LMNA 1611/4885CA2 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.